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Context: Thyroid autoimmunity is the most common coexistent en-
docrinopathy in type 1 diabetes (T1D), Addison’s disease, and pre-
mature ovarian failure (POF). Although the role of autoimmunity is
being investigated in patients with sporadic idiopathic hypoparathy-
roidism (SIH), there is little information on coexistent thyroid
autoimmunity.
Objective: Our objective was to assess the prevalence of thyroid
peroxidase autoantibodies (TPOAb) and thyroid dysfunction in pa-
tients with SIH and its comparison with that in T1D, POF, and
Hashimoto’s thyroiditis (HT) and age- and sex-matched healthy con-
trols (for SIH).
Design and Setting:We conducted a case control study in a tertiary
care setting.
Patients and Methods: Subjects were consecutive patients with
SIH (n  87), T1D (n  100), POF (n  58), and HT (n  47) and
healthy controls (100 females and 64 males). Serum free T3, free T4,
TSH, and TPOAb (normal  34 IU/ml) were measured by electro-
chemiluminescence assay. Subjects with 1) serum TSH at least 5
U/ml along with TPOAb more than 34 IU/ml; 2) TSH at least 10
U/ml but normalTPOAb titers; or 3)Graves’ diseasewere considered
to have thyroid dysfunction.
Results: TPOAb positivity (34 IU/ml) in females was 14.6% in SIH,
24.1% in POF, and 42.1% in T1D compared with 76.6% in HT and 9%
in healthy controls. The frequencies of TPOAb positivity and thyroid
dysfunction in patients with SIH were comparable to those in control
and POF groups, but significantly less than in T1D and HT groups.
Conclusion:The frequencies of TPOAband thyroid dysfunctionwere
not significantly higher in patients with SIH than in healthy controls,
unlike in patientswith T1DandPOF. (JClinEndocrinolMetab 91:
4256–4259, 2006)
THYROID AUTOIMMUNITY is the most common coex-istent endocrinopathy in several autoimmune endo-
crine disorders including type 1 diabetes (T1D), Addison’s
disease, and premature ovarian failure (POF) (1–5). Cluster-
ing of autoimmune endocrine disorders indicates the possi-
bility of shared immunogenetic mechanisms and is relevant
for the clinical management of these disorders (1–5).
The autoimmune basis of sporadic idiopathic hypopara-
thyroidism (SIH) has been under investigation since 1966
when Blizzard et al. (6) reported parathyroid autoantibodies
in 33% of the patients. Generalized T lymphocyte activation
(7) and calcium-sensing receptor autoantibodies (CASRAb)
have been reported in patients with SIH (8–10). Although
these observations suggest the role of autoimmune mecha-
nisms in the pathogenesis of SIH, coexistent thyroid auto-
immunity has not been investigated in these patients (1, 11).
We assessed the presence of thyroid peroxidase autoanti-
bodies (TPOAb) in patients with SIH and compared it to that
observed in T1D, POF, Hashimoto’s thyroiditis (HT), and
age- and sex-matched healthy controls.
Subjects and Methods
Subjects
The study subjects were consecutive patients with SIH (n 87), T1D
(n  100), POF (n  58), and HT (n  47) attending endocrine clinics of
the All India Institute of Medical Sciences (AIIMS), New Delhi, and
healthy controls (100 females and 64 males). Clinical characteristics of
the majority of the patients included in the current study and the di-
agnostic criteria used have been described in detail in our previous
studies (9, 12–16) and in Tables 1 and 2. Briefly, the diagnosis of SIHwas
based on the presence of hypocalcemia, hyperphosphatemia, and inap-
propriately low serum intact PTH. The serum total calcium, phosphorus,
and intact PTH values (median and range) of the study group were 5.5
mg/dl (2.2–7.9), 6.4mg/dl (4.5–11.0), and 3.9 pg/ml (undetectable, 62.0),
respectively. Patients with postsurgical hypoparathyroidism were ex-
cluded. None of the patients had family history suggestive of hypopar-
athyroidism or clinical features of autoimmune ectodermal polyendo-
crinopathy (APECED) syndrome. Autoimmune adrenal involvement
was excluded by demonstrating normal serum cortisol and plasma
ACTH (0800 h) value and absence of adrenal cortical autoantibodies on
indirect immunofluorescence (17). The sex ratio and clinical features
(convulsion, 64.7%; cataract, 53.0%; and intracranial calcification, 74.2%)
of the patients in the current studywere similar to those described earlier
(12–15). Patients with T1D were recruited from the Diabetes of Young
Clinic at AIIMS and included subjects with age at onset of disease less
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than 30 yr and requiring insulin for glycemic control. Sixty percent of
them had a history of ketosis at presentation. Diabetic patients were
categorized according to the classification by the American Diabetes
Association expert committee (18, 19). Patients with fibrocalculous pan-
creatopathy as well as those achieving glycemic control with diet and
oral hypoglycemic agentswere excluded.Of the T1Dpatients, 40.2%had
glutamic acid decarboxylase 65 antibodies positivity. Two of the patients
with T1D had associated celiac disease. Patients with POF were diag-
nosed as follows: age less than 40 yr, secondary amenorrhea more than
6months duration, and serum FSH valuesmore than 40mIU/ml on two
occasions 4–6 wk apart and normal karyotype (16). None of the patients
with POFhad clinical features of adrenal insufficiency, and 0800 h serum
cortisolwas normal in all of them. Patientswith Turner’s syndrome (45,X
or 46,XX/45,X karyotype) and those with a history of pelvic surgery
were excluded.
Subjects with goiter and fine-needle aspiration cytology suggestive of
HT were included as positive controls for thyroid autoimmunity. Males
with HT were excluded because of their limited numbers (n  4).
Healthy controls included volunteers for a task force study for the Indian
Council ofMedical Research to generate normative data on bonemineral
density in healthy north Indian Asians (n  94) and one first-degree
relative each from the family of patients with osteomalacia recruited for
vitamin D receptor polymorphisms analysis (n  70). All the control
subjects had normal serum total calcium and inorganic phosphorus. The
control subjects were matched in a 1:1 ratio to patients with SIH by age
(within 1 yr). Additional controls with age within 1 yr of the mean age
of male and female patients with SIH were included to increase the
statistical power of the study. The serum samples were drawn from the
subjects after institutional ethics committee approval and written in-
formed consent.
Definitions
TPOAb positivity. Serum TPOAb titers greater than 34 IU/ml were con-
sidered positive (Roche, GmbH, Mannheim, Germany). To assess high
titer TPOAb positivity, an arbitrary cutoff of 103 IU/ml (three times
above the normal) was also used.
TABLE 1. Clinical characteristics and thyroid peroxidase positivity and thyroid dysfunction in female patients with SIH
Parameters SIH(n  41)
T1D
(n  57)
HT
(n  47)
POF
(n  58)
Controls
(n  100)
Mean age (yr) 30.2  11.8 23.4  9.9a 34.4  13.6b 29.2  6.6 29.0  12.9b
Mean BMI (kg/m2) 21.8  5.1 19.3  4.0a 22.5  3.9b 22.0  4.2b 23.2  5.1
Duration of clinical symptoms
(yr) (median, range)
4.0 (0.1–27) 9.0 (0.1–25)a 1.0 (0.1–19)b 3.0 (0.1–14)b NA
Subjects with TPOAb  34 IU/
ml (n, %)
6 (14.6%)a,b 24 (42.1%)c 36 (76.6%)d 14 (24.1%)b 9 (9.0%)a
Odds ratio (95% CI) 1.73 (0.57–5.23) 7.35 (3.10–17.42) 33.89 (12.64–86.57) 3.22 (1.29–8.0) NA
Subjects with TPOAb  103
IU/ml (n, %)
5 (12.2%)a 20 (35.1%)c 31 (65.9%)d 11 (19.0%)a,c 8 (8.0%)a
Odds ratio (95% CI) 1.54 (0.48–5.21) 6.21 (2.51–15.35) 22.28 (8.69–57.11) 2.69 (1.01–7.14) NA
Thyroid dysfunction
Group i: subjects with
TPOAb  34 IU/ml and
TSH  5.0 U/ml (n, %)
3 (7.3%)a,c 15 (26.3%)d 34 (72.3%)b 9 (15.5%)c,d 4 (4%)a
Group ii: subjects with TSH
10.0 U/ml and normal
TPOAb (n, %)
1 (2.4%) 5 (8.7%)a 5 (10.6%)a 1 (1.2%) 1 (1%)b
Group iii: Graves’ disease (n) 0 1** 0 2 0
All thyroid dysfunction (i  ii
 iii)
4 (9.7%)a,c 20 (35.0%)d 39 (83.0%)b 12 (20.6%)c,d 5 (5.0%)a
Odds ratio (95% CI) 2.05 (0.52–8.07) 10.27 (3.59–29.37) 92.6 (28.52–300.0) 4.96 (1.64–14.90) NA
Data in the same row with different superscripts are significantly different from each other (ANOVA, post hoc Tukey HSD test, P  0.05
significant). Normal TPOAb  34.0 IU/ml. NA, Not applicable; CI, confidence interval.
**, Patient with T1D had Graves’ disease 10 yr earlier. However, she showed remission following 1-yr course of carbimazole therapy and
converted to hypothyroidism during follow-up and was therefore considered in thyroid dysfunction group i.
TABLE 2. Clinical characteristics and thyroid peroxidase positivity and thyroid dysfunction in male patients with SIH
Parameters SIH(n  46)
T1D
(n  43)
Controls
(n  64)
Mean age (yr) 33.6  14.3b 21.6  8.8a 33.6  17.2b
Mean BMI (kg/m2) 20.6  4.5a,b 18.6  2.3a 22.6  4.8b
Duration of clinical symptoms (yr) (median, range) 5.0 (0.1–35) 4.0 (0.3–22) NA
Subjects with TPOAb  34 IU/ml (n, %) 8 (17.4%)a,b 11 (25.6%)a 6 (9.3%)b
Odds ratio (95% CI) 2.04 (0.65–6.3) 3.32 (1.12–9.82) NA
Subjects with TPOAb  103 IU/ml (n, %) 3 (6.5%)a,b 7 (16.3%)a 2 (3.1%)b
Odds ratio (95% CI) 2.16 (0.35–13.49) 6.03 (1.87–30.58) NA
Thyroid dysfunction
Group i: subjects with TPOAb  34 IU/ml and
TSH  5.0 U/ml (n, %)
4 (8.7%) 5 (11.6%) 2 (3.1%)
Group ii: subjects with TSH  10.0 U/ml
but normal TPOAb (n, %)
0 1 (2.3%) 0
Group iii: Graves’ disease (%) 0 3 (6.9%) 0
All thyroid dysfunction (i  ii  iii) 4 (8.7%) 9 (20.8%)a 2 (3.1%)b
Odds ratio (95% CI) 2.96 (0.52–16.85) 8.21 (1.67- 40.17) NA
Data in same row with different superscripts are significantly different from each other (ANOVA, post hoc Tukey HSD test, P  0.05
significant). Normal TPOAb  34.0 IU/ml. NA, Not applicable; CI, confidence interval.
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Thyroid dysfunction. In the current study, subjects with 1) serum TSH at
least 5 U/ml along with TPOAb greater than 34 IU/ml, 2) TSH at least
10 U/ml but normal TPOAb titers, or 3) Graves’ disease were con-
sidered to have clinically relevant thyroid dysfunction.
Biochemical estimations
Serum samples for the measurement of free T3, free T4, TSH, and
TPOAb were stored at 20 C and assayed together in multiple batches
by Elecsys immunoassay kits auto analyzer (Elecsys-1010, Roche Diag-
nostics,Mannheim, Germany). The normal ranges for serum free T3, free
T4, TSH, and TPOAbwere 3.1–6.8 pmol/liter, 12–22 pmol/liter, 0.27–4.2
IU/ml, and greater than 34.0 IU/ml, respectively. Inter- and intraassay
coefficients of variation for these measurements were 2.2, 2.9, 8.6, and
6.3%; and 2.8, 6.6, 8.7, and 9.5%, respectively. The serum FSH (Medicorp
Inc., Montreal, Quebec, Canada) and intact PTH (Diasorin, Stillwater,
MN; normal range, 13–54 pg/ml) were assayed by using immunora-
diometric kits. Their inter- and intraassay coefficient of variations
ranged from 3.5 to 8.5% and 3.4 to 3.6%, respectively. Quantitative
determination of glutamic acid decarboxylase antibodies (GADAb) was
performed using 125I RIA using a commercial kit (DLD Diagnostica
GMBH, Adlerhorst, Hamburg, Germany). Inter- and intraassay coeffi-
cients of variation for GADAb assay were 5.1 and 2.9% (normal value
1 U/ml).
Statistical analysis
The data are given as mean  sd. Statistical analysis was performed
with SPSS statistical software (version 10.0; SPSS Inc., Chicago, IL). The
significance of differences in the mean age and body mass index (BMI;
kilograms per square meter) of various groups was assessed by using
an ANOVA, followed by Tukey highest significant difference (HSD) test
for post hoc analysis if ANOVA was significant. The 2 test with Yates
correction was used to assess the significance of differences in the fre-
quencies of TPOAb positivity and thyroid dysfunction in different
groups. P value  0.05 was considered significant.
Results
Tables 1 and 2 show the mean age, BMI, frequencies of
TPOAb positivity, and thyroid dysfunction in female and
male patients within the SIH group and their comparison
with other groups. The mean age and BMI of both male and
female patients with SIH were comparable to those of other
groups (Tables 1 and 2). However, the mean age of patients
with T1Dwas significantly less than that of the control group.
TPOAb and thyroid dysfunction in females
The frequency of TPOAb positivity (34 IU/ml) was
14.6% in SIH, 24.1% in POF, 42.1% in T1D, 76.6% in HT, and
9% in the healthy controls. No significant difference was
observed between SIH and the control groups at any of the
two cutoffs used for TPOAb positivity (34 or 103 IU/ml).
However, the frequencies of TPOAb positivity with both
cutoffs were significantly higher in patients with POF, T1D,
and HT than in the control group.
No significant difference was observed in the frequency of
thyroid dysfunction (as defined in Subjects and Methods) be-
tween patients with SIH and the healthy controls (Table 1).
In comparison, the frequencies of thyroid dysfunction were
significantly higher in POF, T1D, and HT groups compared
with the healthy controls. Graves’ disease was observed only
in the patients with POF (n  2) and T1D (n  1) but not in
the SIH group. Across the groups, the majority of patients
with thyroid dysfunction had coexistent TPOAb (Table 1).
TPOAb and thyroid dysfunction in males
No significant difference was observed in the frequency of
TPOAb positivity and thyroid dysfunction at any of the
cutoffs (34 IU/ml or 103 IU/ml) between SIH and the healthy
controls (Table 2). This is in contrast to significantly high
TPOAb positivity and thyroid dysfunction observed in the
T1D group.
The frequency of TPOAb tended to be higher in patients
with T1D who had GADAb positivity compared with those
with no circulating GADAb (43.6 vs. 27.6%; P  0.18). How-
ever, there was no significant difference in the thyroid dys-
function between T1D patients with and without GADAb
positivity (24.1 vs. 25.6%; P  0.94).
Discussion
The autoimmune basis of hypoparathyroidism associated
with APECED syndrome is supported by the presence of
parathyroid autoantibodies (20) and CASRAb in these pa-
tients (8). However, recently Soderbergh et al. (21) could not
observe CASRAb in any of the 90 patients with hypopara-
thyroidism occurring in the setting of autoimmune polyen-
docrine syndrome type 1. The role of autoimmune mecha-
nisms is also being investigated in patients with SIH (9–11),
and there are two reports of CASRAb positivity in these
patients (9, 10). Higher prevalence of coexistent TPOAb is
often used as a surrogate marker for autoimmunity. Jenkins
andWeetman (1) reviewed thyroid autoimmunity in various
autoimmune endocrine disorders and observed its signifi-
cant association with T1D and Addison’s disease. Data on
POF and other endocrine disorders including SIH were not
conclusive because of the scarcity of published information
(1, 11). The present study fills a gap in the world survey of
thyroid autoimmunity in these disorders.
The results of the current study indicate that the frequency
of TPOAb positivity in male and female patients with SIH
was comparable to that of healthy controls, unlike the T1D
and POF groups. The only study available on prevalence of
thyroid autoimmunity in idiopathic hypoparathyroidism
has been by Blizzard et al. (6), where nine of 44 female
patients with hypoparathyroidism had thyroid microsomal
autoantibodies on indirect immunofluorescence test. It is
difficult to compare these results with the current study
because several patients studied by Blizzard had features of
APECED syndrome, a different assay methodology was
used, and statistical significance could not be determined in
the absence of age- and sex-matched controls. In a previous
study of 51 patients with SIH, we did not find a significant
difference in the TPOAb positivity between the cases and the
controls (9). However, the controls were not gender and age
matched. In the current study we have included age- and
sex-matched controls. However, with 41 female and 46 male
patients with SIH and 100 female and 64 male controls, the
current study would have 80% power and 95% confidence
interval to exclude an odds ratio of 4.0 or higher for TPOAb
positivity. A large cohort of 347 patients with SIH and 920
controls would be required to confer statistical significance
andpower to the 1.7 odds ratio of TPOAbpositivity observed
in patientswith SIH. Considering these facts, the preliminary
trend of lower TPOAb positivity observed in patients with
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SIH in comparison to T1D and POF needs further studies
involving a larger number of patients with SIH.
In comparison to SIH, patients with T1D and POF showed
significantly higher prevalence of TPOAb and thyroid dys-
function. The observations of the current study indicating
high prevalence of TPOAb and thyroid dysfunction in pa-
tients with T1D, especially among female subjects, are in
accordance with several previous studies (5, 22), including a
report from our center (18). Recently, Barker et al. (22)
screened a large cohort of 814 patientswith T1Dwithmedian
age of 14.8 yr (10.7–27.1) and median duration of diabetes of
3.4 yr (0.08–10.33) and reported TPOAb and/or thyroglob-
ulin Ab expression in 29%. Thyroid autoimmunity was more
common in females and increased with longer duration of
diabetes (22). In the current study, themean age andduration
of diabetes were 23.4 yr and 9.1 yr, respectively, and may
account for the 42% prevalence of TPOAb in the females. The
association of T1D with thyroid autoimmunity has been
linked to shared immunopathogenetic mechanisms. Human
leukocyte antigen alleles (DR3-DQ2) have been associated
with TPOAb positivity in patients with T1D (22). Patients
with T1D and GADAb have a significantly higher possibility
of TPOAb positivity (22). The trend of higher TPOAb pos-
itivity in patients with T1D who were GADAb positive in
comparison to those with no GADAb positivity is in accor-
dance with the previous observation of Barker et al. (22).
In contrast to T1D, association between POF and thyroid
autoimmunity is yet to be proven conclusively (1, 11). The
largest study to date on thyroid autoimmunity in POF is by
Betterle et al. (4). Of the 50 patientswith POF, 18%had clinical
evidence of autoimmune thyroid disorders, and 10% had
thyroid autoantibodies (4). However, the study was not case
controlled. Shah et al. (23) studied 37 Indian patients with
POF and reported a 22% prevalence of thyroid dysfunction.
The current study including the largest number of subjects
with POF showed 24 and 20.6% prevalence of TPOAb pos-
itivity and thyroid dysfunction, which were significantly
higher than those of controls.
Thus, the results of the present study indicate that the
frequency of TPOAb and thyroid dysfunction is not signif-
icantly higher in patients with SIH than in healthy controls,
unlike patients with T1D and POF. However, the limited
spread of thyroid autoimmunity in patients with SIH needs
further exploration by involving a larger cohort of patients
with SIH using a multicentric approach in view of the rarity
of the disease.
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